Anti-flavivirus compounds and methods of use

US11471443B2 · kind B2 · utility

Assignees

• Florida State University Research Foundation, Inc. · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• The Trustees of the University of Pennsylvania · US

Inventors

• Hengli Tang · Tallahassee, US
• Emily M. Lee · Tallahassee, US
• Wei Zheng · Rockville, US
• Ruili Huang · Rockville, US
• Miao Xu · Hangzhou City, CN
• Wenwei Huang · Rockville, US
• Khalida Shamim · Gaithersburg, US
• Guoli Ming · Philadelphia, US
• Hongjun Song · Madison, US

Key dates

• Filing date: Apr 29, 2020
• Grant date: Oct 18, 2022
• Expiry date: Sep 23, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.